Relazione su invito
Research activities on the production of innovative radionuclides of medical interest at INFN-LNL: The ISOLPHARM and LARAMED projects.
Ballan M., Pupillo G., Andrighetto A., Esposito J., Corradetti S., Vettorato E., Mou L., Cisternino S., Manzolaro M., Martini P., Morselli L., Khwairakpam O.S., Arzenton A., Tosato M., De Dominicis L., Scarpa D., Sciacca G., Lunardon M., Boschi A., Donzella A., Asti M., Mariotti E.
The production of innovative and alternative radionuclides of medical interest is fundamental for the research advancement in the field of radiopharmaceuticals, important tools for the modern nuclear medicine diagnostics and therapy routines. In such framework, at INFN-LNL, thanks to the recent installation of the $70 {MeV}$ proton cyclotron of the SPES (Selective Production of Exotic Species) facility, two complementary accelerator-based projects, ISOLPHARM (ISOL technique for radioPHARMaceuticals) and LARAMED (LAboratory of RAdionuclides for MEDicine), were outlined. The first one will explore the new opportunities and innovative radionuclides such as $^{111}Ag$ provided by the SPES ISOL (Isotope Separation On-Line) facility, where the combination of the electromagnetic mass separation, typical of the ISOL technique and an eventual chemical separation process can ensure high specific activity. LARAMED will be focused on the direct-activation method exploring the proton-based production of $^{99{m}}Tc$, $^{67}Cu$, $^{52/51}Mn$, $^{47}Sc$ and recently Tb-isotopes. The current research activities up to the preclinical tests for both projects will be presented in detail.